Unilabs Announces Global Strategic Alliance in Companion Diagnostic Testing with Biogen Idec for STRATIFY- JCV
Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV. The test is a highly sensitive two-step ELISA assay used to detect anti-JCV antibodies. The presence of anti-JCV antibodies is one in a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of TYSABRI-treated patients developing progressive multifocal leukoencephalopathy (PML).
To support customers, ordering needs and volume of samples, Unilabs and Biogen Idec have also developed a closed web interface to allow neurologists to order sampling and shipping materials, register courier sample pick up details, and request language and format of analytical reports. Also, neurologists can seek sampling, shipping and medical support in five major languages through a multilingual call centre. The project is centralised to and managed by Unilabs in Copenhagen.
Natascha Schill, Biogen Idec commented: “Unilabs is an independent commercial laboratory with a very high reputation, a strong European footprint and excellent international skills, competences and agility. We are very happy to work with Unilabs”
According to Yvonne Lech, Managing Director of Unilabs Denmark, “The experiences and the innovations created for this project can be applied in the future to create added customer value for future global Companion Diagnostic projects.”
Companion Diagnostics are expected to be the future for many new medicines. This collaboration is a clear example of this trend since it combines our distinct competencies and offers our clients a truly international high-quality service.
Unilabs - A leader in diagnostic services
Unilabs
is a leading diagnostic services company. We operate more than 100
laboratories and 30 radiology units in Belgium, Denmark, Finland,
France, Italy, Norway, Portugal, Russia, Spain, Sweden, Switzerland, and
the United Kingdom. Our customers are both public and private.
We
serve: hospitals, outpatients clinics, GPs, occupational health units,
insurance companies, drug development companies and CROs. We supply
medical laboratory analyses and services within clinical biochemistry,
haematology, transfusion medicine, microbiology, serology, immunology,
special chemistry, nuclear medicine, molecular biology, genetic testing,
histopathology, and clinical trials. Our radiology units supply services
within conventional X-ray, mammography, MRI, CT, ultrasound,
fluoroscopy, osteoporosis, nuclear medicine and teleradiology. For more
information please visit
www.unilabs.com
.
Contact:
Unilabs a.s.:
Yvonne Lech, Managing Director
Tel: +45
23 44 12 84
email: yvonne.lech@unilabs.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider platformen med tilføjelsen af Liberty IT Consulting Group fra Australien21.8.2025 18:12:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine digitale transformationskompetencer yderligere med Liberty IT, der er en førende leverandør af digital transformation i virksomhedsklassen inden for finansielle services. Liberty IT, der blev grundlagt i 2016 og har hovedkontor i Australien, specialiserer sig i teknologirådgivning for førende finansielle organisationer såsom banker, formueforvaltere og børsen. Virksomheden er specialiseret inden for modernisering af banksystemer, betalingsløsninger, data og digitale løsninger med særligt fokus på implementering af cloudbaserede løsninger, systemintegration, datamigrering, programmering, DevOps, kunstig intelligens og fusioner og integrationer af virksomheder. Med et stærkt renomme på markedet samarbejder Liberty IT med kunder om at levere skalerbare platforme, øge driftsmæssig effektivitet, optimere ydeevne, reducere omkostninger, maksimere sandsynligheden for succesfuld projektlevering og accelerere digitale transformationsinitiativer. "Samarbejdet med
Veridas Identity Fraud Solutions Now Available on AWS Marketplace21.8.2025 18:05:00 CEST | Press release
Veridas, a global leader in identity verification and biometric solutions, today announced that its Identity Verification (IDV) platformis now available on Amazon Web Services (AWS) Marketplace. This launch puts the full power of Veridas’ fraud prevention and identity verification capabilities in the hands of millions of AWS customers worldwide, making secure digital trust only a click away. As identity fraud rises exponentially — with threats from synthetic identities, deepfakes, and injection attacks — Veridas delivers a cloud-native solution combining facial biometrics, AI-driven document authentication, and certified liveness detection. The platform shields enterprises from fraud while enabling seamless onboarding in seconds. “Live since 2017, our IDV platform already protects more than 300 clients in 25 countries against advanced fraud such as deepfakes and injection attacks, with 100% proprietary technology, global coverage, and international compliance,” said Eduardo Azanza, CEO
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™21.8.2025 17:21:00 CEST | Press release
Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud to be supporting Steel Therapeutics at this key stage of their development journey,” said Steve Mason, Co-COO at Altasciences. “Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.” Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach b
Media alert | Masdar receives ‘AA-’ credit rating with stable outlook by S&P Global Ratings in further recognition of the financial strength of the business21.8.2025 15:55:00 CEST | Press release
Masdar has been assigned an ‘AA-’ credit rating with a stable outlook by S&P Global Ratings, reinforcing its position as a global clean energy leader. This new rating reflects Masdar's diversified global position, strong growth prospects, and disciplined financial policies, including the allocation of green bond proceeds to finance the construction of new projects. With top credit ratings now secured from Moody’s (A1), Fitch (AA-) and S&P (AA-), Masdar continues to be recognized as one of the most financially robust renewable energy companies worldwide. This enables the Company to continue to drive responsible expansion and deliver inclusive progress across key international markets. The rating is also underpinned by the strong support of the Company's three shareholders - Abu Dhabi National Oil Company (ADNOC), Mubadala Investment Company, and Abu Dhabi National Energy Company PJSC (TAQA) - as well as the Government of Abu Dhabi. View source version on businesswire.com: https://www.bu
Verb Technology Announces $780 Million in Treasury Assets to Advance its TON Treasury Strategy21.8.2025 15:20:00 CEST | Press release
Verb Technology Company, Inc. (Nasdaq: VERB) (to be renamed Ton Strategy Company) (the “Company”) today announced treasury assets exceeding $780 million, including $713 million1 of Toncoin ($TON), the native cryptocurrency of The Open Network (“TON”) Blockchain, and $67 million of cash. This is an important milestone in the Company’s implementation of its previously announced $TON treasury strategy. Today’s news follows the Company’s August 8 closing of a $558 million private placement joined by more than 110 institutional and crypto-native investors. The Company used the majority of proceeds from the private placement to acquire $TON as its primary treasury reserve asset. "Crossing $780 million in assets just days after our private placement reflects the conviction behind $TON,” said Manuel Stotz, Executive Chairman of the Company. “This is more than building a balance sheet; it’s about contributing to the security of TON blockchain – where participants can build, transact, and benefi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom